title: Long-term effects of early nutritional support with new enterotropic peptide-based formula vs. standard enteral formula in HIV-infected patients: randomized prospective trial.
abstract: Despite association with adverse clinical outcome, human immunodeficiency virus (HIV)-associated malnutrition has been relatively refractory to conventional nutrition management. Consequently, a prospective randomized trial was conducted to evaluate a new peptide-based enteral formula (NEF) in contrast to a standard enteral formula (SEF) in patients with HIV infection. Eighty early-stage largely asymptomatic patients were randomized into a dietary regimen supplemented with either a ready-to-feed NEF (18.7% protein, 65.5% carbohydrate, 15.8% fat; 1.28 kcal/ml) or SEF (14% protein, 55% carbohydrate, 31% fat; 1.06 kcal/ml). Patients received 2-3 8-oz cans of the NEF or SEF supplement per day for 6 mo. Parameters evaluated at 0 (baseline), 3, and 6 mo included adherence, weight change, anthropometric measurements, serum biochemical indices, gastrointestinal symptoms, physical performance, and intercurrent health events (including hospitalizations). For the 56 evaluable patients, those supplemented with NEF maintained their body weight significantly (p = 0.04) better, had significantly (p = 0.03) more stable triceps skin-fold measurements, and had significantly (p = 0.04) lower blood urea nitrogen than patients consuming the SEF supplement. Consumption of the NEF supplement was also associated with significantly reduced hospitalizations during the 3- to 6-mo evaluation period (p = 0.02). The NEF supplement was well tolerated and did not result in untoward clinical effects. These data suggest that supplemental use of an NEF provides superior nutritional management compared with an SEF for patients with early-stage HIV infection.
authors.affiliation: UCLA-Harbor Medical Center, Torrance.
authors.forename: R T
authors.initials: RT
authors.lastname: Chlebowski
authors.forename: G
authors.initials: G
authors.lastname: Beall
authors.forename: M
authors.initials: M
authors.lastname: Grosvenor
authors.forename: L
authors.initials: L
authors.lastname: Lillington
authors.forename: N
authors.initials: N
authors.lastname: Weintraub
authors.forename: C
authors.initials: C
authors.lastname: Ambler
authors.forename: E W
authors.initials: EW
authors.lastname: Richards
authors.forename: B C
authors.initials: BC
authors.lastname: Abbruzzese
authors.forename: M A
authors.initials: MA
authors.lastname: McCamish
authors.forename: F O
authors.initials: FO
authors.lastname: Cope
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D001806:Blood Urea Nitrogen; D001835:Body Weight; D003404:Creatinine / Q000097:blood; D004044:Dietary Proteins / Q000008:administration & dosage / Q000627:therapeutic use*; D002149:Energy Intake; D004750:Enteral Nutrition; D005260:Female; D005500:Follow-Up Studies; D005526:Food, Formulated; D015658:HIV Infections / Q000150:complications / Q000178:diet therapy*; D006760:Hospitalization; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011446:Prospective Studies; D011502:Protein-Energy Malnutrition / Q000209:etiology / Q000517:prevention & control*; D012709:Serum Albumin / Q000032:analysis; D012885:Skinfold Thickness
chemical_list: D004044:Dietary Proteins; D012709:Serum Albumin; D003404:Creatinine